155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Tarlatamab, a bispecific T-cell engager (BiTE®) immunotherapy targeting delta-like ligand 3, has shown promising outcomes in previously treated small cell lung cancer (SCLC). We evaluated the safety of a reduced 6-8 hour (h) monitoring period with tarlatamab in an outpatient setting in the phase 1 DeLLphi-300 study.
Authors
- Rafał Stec (ORCID: https://orcid.org/0000-0002-3291-6422)
- E. Felip
- S. Gadgeel
- Amanda Parkes (ORCID: https://orcid.org/0000-0002-2599-6460)
- Anne C. Chiang (ORCID: https://orcid.org/0000-0002-2111-4694)
- A. Dowlati
- N. Steeghs
- H.H.F. Loong
- Weiguo Jiang (ORCID: https://orcid.org/0000-0002-1352-1046)
- J. Carlisle
- L. Paz-Ares
- Ali Hamidi (ORCID: https://orcid.org/0000-0002-1096-5119)
- Noemı́ Reguart (ORCID: https://orcid.org/0000-0001-8190-499X)
- Philipp J. Jost (ORCID: https://orcid.org/0000-0003-2454-0362)
- M.E. Olmedo García
Institutions
- Hebron University (PS)
- Amgen (United States) (US)
- Emory University (US)
- Chinese University of Hong Kong (HK)
- Medical University of Graz (AT)
- Medical University of Warsaw (PL)
- University Hospitals of Cleveland (US)
- The Netherlands Cancer Institute (NL)
- Yale University (US)
- Hospital Universitario 12 De Octubre (ES)
- Prince of Wales Hospital (CN)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100784
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Merck KGaA
- Exelixis
- Les Laboratories Pierre Fabre
- Mirati Therapeutics
- BeiGene
- Incyte
- Actuate Therapeutics
- Seagen
- Astellas Pharma
- Sociedad Española de Oncología Médica
- Servier
- Ipsen
- Grifols
- Genentech
- Takeda Pharmaceuticals International
- Daiichi Sankyo Europe
- Cilag